JP2020509022A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020509022A5 JP2020509022A5 JP2019547113A JP2019547113A JP2020509022A5 JP 2020509022 A5 JP2020509022 A5 JP 2020509022A5 JP 2019547113 A JP2019547113 A JP 2019547113A JP 2019547113 A JP2019547113 A JP 2019547113A JP 2020509022 A5 JP2020509022 A5 JP 2020509022A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- hydrogen
- protecting group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 68
- 229910052739 hydrogen Inorganic materials 0.000 claims 67
- 239000001257 hydrogen Substances 0.000 claims 67
- 125000000623 heterocyclic group Chemical group 0.000 claims 55
- 125000001072 heteroaryl group Chemical group 0.000 claims 50
- 150000002431 hydrogen Chemical class 0.000 claims 49
- 125000003118 aryl group Chemical group 0.000 claims 37
- 125000004452 carbocyclyl group Chemical group 0.000 claims 36
- 125000000304 alkynyl group Chemical group 0.000 claims 34
- 238000000034 method Methods 0.000 claims 34
- 125000003342 alkenyl group Chemical group 0.000 claims 32
- 229910052736 halogen Inorganic materials 0.000 claims 31
- 150000002367 halogens Chemical class 0.000 claims 31
- 239000013078 crystal Substances 0.000 claims 28
- 239000000651 prodrug Substances 0.000 claims 28
- 229940002612 prodrug Drugs 0.000 claims 28
- 150000003839 salts Chemical class 0.000 claims 28
- 239000012453 solvate Substances 0.000 claims 28
- 150000001875 compounds Chemical class 0.000 claims 25
- 125000002252 acyl group Chemical group 0.000 claims 19
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 14
- 150000004677 hydrates Chemical class 0.000 claims 14
- 125000004429 atom Chemical group 0.000 claims 11
- 125000004430 oxygen atom Chemical group O* 0.000 claims 11
- 229910052717 sulfur Inorganic materials 0.000 claims 11
- 125000004434 sulfur atom Chemical group 0.000 claims 11
- 229910052757 nitrogen Inorganic materials 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 6
- 125000000547 substituted alkyl group Chemical group 0.000 claims 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 125000004193 piperazinyl group Chemical group 0.000 claims 4
- 125000003386 piperidinyl group Chemical group 0.000 claims 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 108091000080 Phosphotransferase Proteins 0.000 claims 2
- 208000012641 Pigmentation disease Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000020233 phosphotransferase Human genes 0.000 claims 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 102000013760 Microphthalmia-Associated Transcription Factor Human genes 0.000 claims 1
- 108010050345 Microphthalmia-Associated Transcription Factor Proteins 0.000 claims 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000005549 heteroarylene group Chemical group 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 0 *C1C(C2CCCCC2)=CC2C=C=C/C(/C#N)=C\CC2CC1 Chemical compound *C1C(C2CCCCC2)=CC2C=C=C/C(/C#N)=C\CC2CC1 0.000 description 3
- SAWXBOBEGFDMNS-MSVVQRAFSA-N CC(CC(C=C)/C=C(\C)/N(CC1)CCN1NC)C(C)=N Chemical compound CC(CC(C=C)/C=C(\C)/N(CC1)CCN1NC)C(C)=N SAWXBOBEGFDMNS-MSVVQRAFSA-N 0.000 description 1
- BTIMFUJIIYYWIM-UHFFFAOYSA-N CC1=C(C)N=CCC1CC=C Chemical compound CC1=C(C)N=CCC1CC=C BTIMFUJIIYYWIM-UHFFFAOYSA-N 0.000 description 1
- MTAUERSRIFOGMG-JLHYYAGUSA-N CCCCN(C)/C(/CC)=C/C=C(C)C Chemical compound CCCCN(C)/C(/CC)=C/C=C(C)C MTAUERSRIFOGMG-JLHYYAGUSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023043357A JP2023088968A (ja) | 2017-02-28 | 2023-03-17 | Ｓｉｋインヒビターとしてのピリミドピリミジノンの使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762464675P | 2017-02-28 | 2017-02-28 | |
| US62/464,675 | 2017-02-28 | ||
| US201762472468P | 2017-03-16 | 2017-03-16 | |
| US62/472,468 | 2017-03-16 | ||
| PCT/US2018/020335 WO2018160774A1 (en) | 2017-02-28 | 2018-02-28 | Uses of pyrimidopyrimidinones as sik inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023043357A Division JP2023088968A (ja) | 2017-02-28 | 2023-03-17 | Ｓｉｋインヒビターとしてのピリミドピリミジノンの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020509022A JP2020509022A (ja) | 2020-03-26 |
| JP2020509022A5 true JP2020509022A5 (enExample) | 2021-04-15 |
| JP7296318B2 JP7296318B2 (ja) | 2023-06-22 |
Family
ID=63370223
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019547113A Active JP7296318B2 (ja) | 2017-02-28 | 2018-02-28 | Ｓｉｋインヒビターとしてのピリミドピリミジノンの使用 |
| JP2023043357A Pending JP2023088968A (ja) | 2017-02-28 | 2023-03-17 | Ｓｉｋインヒビターとしてのピリミドピリミジノンの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023043357A Pending JP2023088968A (ja) | 2017-02-28 | 2023-03-17 | Ｓｉｋインヒビターとしてのピリミドピリミジノンの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11285158B2 (enExample) |
| EP (1) | EP3589284A4 (enExample) |
| JP (2) | JP7296318B2 (enExample) |
| KR (1) | KR20190120331A (enExample) |
| CN (1) | CN111163771B (enExample) |
| AU (1) | AU2018226771B2 (enExample) |
| BR (1) | BR112019017741A2 (enExample) |
| CA (1) | CA3054809A1 (enExample) |
| RU (1) | RU2019129727A (enExample) |
| WO (1) | WO2018160774A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2954186A1 (en) | 2014-07-21 | 2016-01-28 | Dana-Farber Cancer Institute, Inc. | Imidazolyl kinase inhibitors and uses thereof |
| AU2017291812B2 (en) * | 2016-07-05 | 2023-12-14 | Dana-Farber Cancer Institute, Inc. | Bicyclic urea kinase inhibitors and uses thereof |
| WO2018053373A1 (en) | 2016-09-16 | 2018-03-22 | The General Hospital Corporation | Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis |
| EP3589284A4 (en) * | 2017-02-28 | 2020-12-16 | The General Hospital Corporation | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| US20230048132A1 (en) * | 2018-12-28 | 2023-02-16 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
| US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
| WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
| WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| HRP20231310T1 (hr) | 2019-05-10 | 2024-02-02 | Deciphera Pharmaceuticals, Llc | Heteroarilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene |
| HUE065486T2 (hu) | 2019-05-10 | 2024-05-28 | Deciphera Pharmaceuticals Llc | Fenilaminopirimidinamid autophágia inhibitorok és azok felhasználási eljárásai |
| ES3072710T3 (en) | 2019-06-17 | 2026-07-03 | Deciphera Pharmaceuticals Llc | Aminopyrimidine amide autophagy inhibitors and methods of use thereof |
| WO2021030537A1 (en) | 2019-08-14 | 2021-02-18 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| CR20220170A (es) | 2019-10-11 | 2022-10-10 | Incyte Corp | Aminas bicíclicas como inhibidoras de la cdk2 |
| GB201915828D0 (en) | 2019-10-31 | 2019-12-18 | Cancer Research Tech Ltd | Compounds, compositions and therapeutic uses thereof |
| GB201915831D0 (en) | 2019-10-31 | 2019-12-18 | Cancer Research Tech Ltd | Compounds, compositions and therapeutic uses thereof |
| EP3901151B1 (en) | 2020-04-21 | 2026-04-01 | iOmx Therapeutics AG | Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof |
| IL297714A (en) | 2020-04-28 | 2022-12-01 | Iomx Therapeutics Ag | Bicyclic kinase inhibitors and their uses |
| CN117136061A (zh) * | 2020-09-21 | 2023-11-28 | 索尔特戈公司 | Sik抑制剂及其使用方法 |
| WO2022116943A1 (zh) * | 2020-12-02 | 2022-06-09 | 上海瑛派药业有限公司 | 取代的稠合双环化合物作为激酶抑制剂及其应用 |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| WO2023067021A1 (en) | 2021-10-19 | 2023-04-27 | Iomx Therapeutics Ag | A synthesis scheme and procedures for preparing a sik3 inhibitor and intermediates thereof |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| CN114414681B (zh) * | 2021-12-30 | 2024-10-11 | 珠海天祥粤澳质量技术服务有限公司 | 一种同时测定化妆品中的多种色素的方法 |
| EP4257132A1 (en) | 2022-04-08 | 2023-10-11 | iOmx Therapeutics AG | Sik3 inhibitors for treating diseases resistant to death receptor signalling |
| US20250340556A1 (en) * | 2022-05-17 | 2025-11-06 | Soltego, Inc. | Pyrimidopyrimidone compounds and methods of use thereof |
| CN121772920A (zh) * | 2023-09-12 | 2026-03-31 | 丹娜-法伯癌症研究院 | 高级别浆液性癌的治疗 |
| WO2025157389A1 (en) | 2024-01-22 | 2025-07-31 | Iomx Therapeutics Ag | Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors |
| CN118546871B (zh) * | 2024-05-10 | 2025-05-06 | 未来智人再生医学研究院(广州)有限公司 | 一种人多能干细胞分化为间充质干细胞的方法 |
| WO2026117094A1 (ko) * | 2024-11-29 | 2026-06-04 | (주)파로스아이바이오 | 피리도[3,4-d]피리미딘-8-온 유도체의 폐암 예방, 개선 또는 치료 용도 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4231559B2 (ja) | 1997-04-23 | 2009-03-04 | オリザ油化株式会社 | リポキシゲナーゼ阻害剤 |
| DE69939168D1 (de) | 1998-05-26 | 2008-09-04 | Warner Lambert Co | Bicyclische pyrimidine und bicyclische 3,4-dihydropyrimidine als inhibitoren der zellvermehrung |
| PL347432A1 (en) * | 1998-10-23 | 2002-04-08 | Hoffmann La Roche | Bicyclic nitrogen heterocycles |
| DE60033307T2 (de) | 1999-10-21 | 2007-07-12 | F. Hoffmann-La Roche Ag | Heteroalkylamino-substituierte bicyclische stickstoffheterocyclen als p38-proteinkinase-inhibitoren |
| AU2003225161A1 (en) * | 2002-04-24 | 2003-11-10 | Koo, Han-Mo | Enhancement of human epidermal melanogenesis |
| US7084270B2 (en) | 2002-08-14 | 2006-08-01 | Hoffman-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
| DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
| US20060094013A1 (en) | 2002-08-21 | 2006-05-04 | Hiroshi Takemori | Salt-inducible kinases 2 and use thereof |
| US7129351B2 (en) | 2002-11-04 | 2006-10-31 | Hoffmann-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
| WO2004048343A1 (en) | 2002-11-28 | 2004-06-10 | Schering Aktiengesellschaft | Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents |
| CA2521124A1 (en) | 2003-04-10 | 2004-10-21 | F. Hoffmann-La Roche Ag | Pyrimido compounds |
| US7504396B2 (en) | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| US7442698B2 (en) | 2003-07-24 | 2008-10-28 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| AU2004260689B8 (en) | 2003-07-29 | 2008-05-15 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| MXPA06014247A (es) | 2004-06-10 | 2007-03-12 | Irm Llc | Compuestos y composiciones como inhibidores de la proteina quinasa. |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| WO2006024486A2 (en) | 2004-08-31 | 2006-03-09 | F. Hoffmann-La Roche Ag | Amide derivatives of 3-phenyl dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents |
| WO2006024545A1 (en) | 2004-09-03 | 2006-03-09 | Stichting Voor De Technische Wetenschappen | Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes |
| US8211929B2 (en) | 2004-12-30 | 2012-07-03 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
| AU2006229995A1 (en) | 2005-03-25 | 2006-10-05 | Glaxo Group Limited | Process for preparing pyrido(2,3-d)pyrimidin-7-one and 3,4-dihydropyrimido(4,5-d)pyrimidin-2(1H)-one derivatives |
| ME00011A (me) | 2005-12-21 | 2009-02-10 | Novartis Ag | Derivati pirimidinilaril uree kao fgf inhibitori |
| JP2009537520A (ja) | 2006-05-15 | 2009-10-29 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Ｆｇｆ受容体キナーゼ阻害剤のための組成物および方法 |
| WO2008060248A1 (en) | 2006-11-15 | 2008-05-22 | S*Bio Pte Ltd. | Indole sustituted pyrimidines and use thereof in the treatment of cancer |
| BRPI0819453A2 (pt) | 2007-11-28 | 2014-10-07 | Dana Farber Cancer Inst Inc | Composto, métodos para tratar um distúrbio relacionado com atividade de cinase, para tratar câncer em um paciente, para inibir a atividade de cinase e para identificar um composto que modula a atividade de cinase de bcr-abl, composição farmacêutica, e, kit |
| US20100056524A1 (en) | 2008-04-02 | 2010-03-04 | Mciver Edward Giles | Compound |
| WO2009152027A1 (en) | 2008-06-12 | 2009-12-17 | Merck & Co., Inc. | 5,7-dihydro-6h-pyrrolo[2,3-d]pyrimidin-6-one derivatives for mark inhibition |
| CA2732520A1 (en) | 2008-08-05 | 2010-02-11 | Merck Sharp & Dohme Corp. | Therapeutic compounds |
| JP2013508285A (ja) | 2009-10-14 | 2013-03-07 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃ型肝炎の処置のための組成物 |
| CN102816162B (zh) | 2011-06-10 | 2016-04-27 | 中国科学院广州生物医药与健康研究院 | 嘧啶并嘧啶酮类化合物及其药用组合物和应用 |
| MX347765B (es) | 2011-09-30 | 2017-05-12 | Oncodesign Sa | Inhibidores macrociclicos de la quinasa flt3. |
| JP6106685B2 (ja) | 2011-11-17 | 2017-04-05 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤 |
| GB201204384D0 (en) | 2012-03-13 | 2012-04-25 | Univ Dundee | Anti-flammatory agents |
| SG11201406584TA (en) | 2012-04-24 | 2014-11-27 | Vertex Pharma | Dna-pk inhibitors |
| US9260426B2 (en) | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
| CA2906262A1 (en) | 2013-03-15 | 2014-09-18 | Oncodesign S.A. | Macrocyclic salt-inducible kinase inhibitors |
| AU2014287209B2 (en) | 2013-07-09 | 2019-01-24 | Dana-Farber Cancer Institute, Inc. | Kinase inhibitors for the treatment of disease |
| MA38393B1 (fr) | 2014-03-13 | 2018-11-30 | Sanofi Sa | Composés hétéroaryle et utilisations associées |
| CA2954186A1 (en) | 2014-07-21 | 2016-01-28 | Dana-Farber Cancer Institute, Inc. | Imidazolyl kinase inhibitors and uses thereof |
| WO2016014551A1 (en) | 2014-07-21 | 2016-01-28 | Dana-Farber Cancer Institute, Inc. | Macrocyclic kinase inhibitors and uses thereof |
| EP3177295A4 (en) | 2014-08-08 | 2018-06-13 | Dana Farber Cancer Institute, Inc. | Uses of salt-inducible kinase (sik) inhibitors |
| KR101850282B1 (ko) | 2014-11-26 | 2018-05-31 | 한국과학기술연구원 | 단백질 키나아제 저해제로 유용한 헤테로아릴아민 유도체 |
| CN104482860B (zh) | 2014-12-05 | 2017-10-31 | 浙江大学宁波理工学院 | 鱼类形态参数自动测量装置和方法 |
| AU2017291812B2 (en) * | 2016-07-05 | 2023-12-14 | Dana-Farber Cancer Institute, Inc. | Bicyclic urea kinase inhibitors and uses thereof |
| WO2018053373A1 (en) | 2016-09-16 | 2018-03-22 | The General Hospital Corporation | Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis |
| EP3589284A4 (en) * | 2017-02-28 | 2020-12-16 | The General Hospital Corporation | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS |
-
2018
- 2018-02-28 EP EP18760857.5A patent/EP3589284A4/en active Pending
- 2018-02-28 WO PCT/US2018/020335 patent/WO2018160774A1/en not_active Ceased
- 2018-02-28 AU AU2018226771A patent/AU2018226771B2/en active Active
- 2018-02-28 CN CN201880027619.8A patent/CN111163771B/zh active Active
- 2018-02-28 KR KR1020197028441A patent/KR20190120331A/ko not_active Ceased
- 2018-02-28 BR BR112019017741A patent/BR112019017741A2/pt not_active Application Discontinuation
- 2018-02-28 RU RU2019129727A patent/RU2019129727A/ru unknown
- 2018-02-28 JP JP2019547113A patent/JP7296318B2/ja active Active
- 2018-02-28 CA CA3054809A patent/CA3054809A1/en active Pending
- 2018-02-28 US US16/489,462 patent/US11285158B2/en active Active
-
2021
- 2021-11-22 US US17/532,215 patent/US11878019B2/en active Active
-
2023
- 2023-03-17 JP JP2023043357A patent/JP2023088968A/ja active Pending
- 2023-11-29 US US18/522,929 patent/US20240245695A1/en active Pending